Sternberg CN - Search Results

1

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. Among authors: sternberg cn. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Free article. Clinical Trial.

2

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ. Seidman AD, et al. Among authors: sternberg cn. Cancer. 1991 Dec 15;68(12):2561-5. doi: 10.1002/1097-0142(19911215)68:12<2561::aid-cncr2820681205>3.0.co;2-g. Cancer. 1991. PMID: 1933802 Clinical Trial.

3

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.

Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Geller NL, et al. Among authors: sternberg cn. Cancer. 1991 Mar 15;67(6):1525-31. doi: 10.1002/1097-0142(19910315)67:6<1525::aid-cncr2820670611>3.0.co;2-8. Cancer. 1991. PMID: 2001540

4

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. Sternberg CN, et al. Cancer. 1989 Dec 15;64(12):2448-58. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. Cancer. 1989. PMID: 2819654

5

Chemotherapeutic management of invasive bladder carcinoma.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Geller N, et al. Sternberg CN, et al. Eur Urol. 1988;14 Suppl 1:19-20. doi: 10.1159/000473033. Eur Urol. 1988. PMID: 3053199 Clinical Trial. No abstract available.

6

Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.

Sternberg CN, Yagoda A, Scher HI. Sternberg CN, et al. Prog Clin Biol Res. 1988;277:45-51. Prog Clin Biol Res. 1988. PMID: 3054909 Clinical Trial. No abstract available.

7

Current status of chemotherapy for urothelial tract tumors.

Sternberg CN, Scher HI. Sternberg CN, et al. Oncology (Williston Park). 1987 Jul;1(5):41-50, 60. Oncology (Williston Park). 1987. PMID: 3079483 Review.

8

M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.

Sternberg CN, Yagoda A, Scher HI, Whitmore WF Jr, Herr HW, Morse MJ, Sogani PC, Watson RC, Hollander PS, Fair WR. Sternberg CN, et al. Prog Clin Biol Res. 1988;260:481-5. Prog Clin Biol Res. 1988. PMID: 3283768 Clinical Trial. No abstract available.

9

Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.

Sternberg CN, Yagoda A, Scher HI, Whitmore WF Jr, Herr HW, Morse MJ, Sogani PC, Bosl G, Watson RC, Hollander PS, et al. Sternberg CN, et al. Prog Clin Biol Res. 1988;260:551-5. Prog Clin Biol Res. 1988. PMID: 3283770 Review. No abstract available.

10

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, et al. Sternberg CN, et al. J Urol. 1988 Mar;139(3):461-9. doi: 10.1016/s0022-5347(17)42494-3. J Urol. 1988. PMID: 3343727

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

445 results

Search Page